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data showed focalized slow spike – wave: theta waves right F – C – T and T posterior spike. 
Hyperventilation has induced F bilateral extension, without secondary generalization. Photic 
stimulation test maintains focalized epileptic activity. Lamotrigine was initiated in increasing 
doses reaching the therapeutic dose – 200 mg/24 hours. Epileptic seizures have not recurred. 
Free period of seizures - 3 years with antiepileptic treatment. EEG and cerebral MRI monitoring 
were performed regularly, once a year over the last 3 years. Cerebral MRI did not reveal adjacent 
lesions. EEG showed the disappearance of sharp waves and the persistence of slow F – C right 
waves.  
Conclusions. According to the literature data, the seizures could repeat at any time, i.e. over 5 
years or 10 after the stroke. In the 3-year period without seizures probably there was no 
transformation of a structurally damaged brain into an epileptic one. The last definition of 
epilepsy by R. Fisher confirmed that one epileptic seizure cannot be epilepsy. The severity and 
location of the infarction advocates a vascular epilepsy, not epileptogenic foci. 
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Background. Chronic lymphocytic leukemia (CLL) is the most common form of adult leukemia 
in the western European countries and is characterized by the relentless accumulation of 
monoclonal B cells with the appearance of small mature lymphocytes and with a characteristic 
immunophenotype. Even with the right treatment, this disease is known to have a variable 
course: some patients die within one year after diagnosis while others live for longer than ten 
years.  
Case report. A 59-year-old female with a past medical history of ischemic cardiopathy and 
hypothyroidism was admitted to the Haematology Unit of Mures County Emergency Hospital 
with severe anemia, chronic fatigue and leukocytosis. After the anemia was corrected, the 
diagnosis of chronic lymphocytic leukemia was confirmed by complete blood count and 
immunophenotyping for which the patients was only observed for 2 years. Due to the secondary 
severe anemia the treatment with Fludarabine is started as monochemotherapy first line 
treatment. After one month the patient is hospitalized with severe anemia with Coombs’ test 
positive for which methylprednisolone is administered for one week and COP chemotherapy is 
induced. Because of the gastrointestinal side effects, the COP chemotherapy is ceased and 
Fludarabine treatment is reintroduced. The treatment is continued for one year but the multiple 
side effects (hemolytic anemia, herpes zoster, Listeria meningitis) determined cessation of 
Fludarabine and Chlorambucil treatment was introduced. The treatment with Chlorambucil was 
continued for 3 years. Even though the patient supported well the treatment, the splenomegaly 
has progressively increased (from 3 cm to 8 cm) and the infectious diseases appeared 
(Acinetobacter pneumonia and pharyngeal candidiasis).  
Conclusions. Even though the treatment is accordingly to the actual international guides, the 
individual responsibility to the drugs and the unpredictable evolution of this disease may be a 
challenge in treating chronic lymphocytic leukemia. 
Key words: chronic lymphocytic leukemia, treatment, drug selection, side effects 
 
20. FORENSIC ASPECTS OF NON-TRAUMATIC INTRACEREBRAL 
HEMORRHAGE: A CASE REPORT 
